Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

Pittsburgh-based biotech company CytoAgents is launching into phase one of clinical trials this month on a drug designed to treat people with COVID-19 who develop serious respiratory distress when their immune system overreacts to the virus.

According to CytoAgents CEO Teresa Whalen, severe illness in some patients is triggered by a cytokine storm which is an excessive immune response that attacks the body. She said the drug could be particularly helpful for someone hospitalized with COVID-19.

Read more…